TCR测序识别远处转移与非远处转移甲状腺肿瘤的独特免疫组库
本回顾性研究对2012至2018年收集的临床样本行T细胞受体测序(TCR-seq),纳入68例不同转移状态的甲状腺乳头状癌(PTC)患者与21例良性结节患者。结果显示,恶性肿瘤TCRβ多样性在血液和肿瘤样本中均显著高于良性结节;伴远处转移或侵袭性的恶性肿瘤TCRβ多样性低于无转移或无侵袭者;远处转移患者肿瘤与血液TCRβ组库相似性显著;基于重叠CDR3克隆型构建的分类器区分远处转移个体的曲线下面积为83.8%。
要点
- 恶性肿瘤TCRβ多样性在血液(P<.01)和肿瘤(P<.001)中均显著高于良性结节。
- 伴远处转移或侵袭性的恶性肿瘤TCRβ多样性低于无转移(P<.01)或无侵袭(P<.01)者。
- 基于重叠CDR3克隆型构建的分类器区分远处转移个体的曲线下面积为83.8%。
核心结论
- TCR-seq的可用性与可靠性使其有望将这些内在特征转化为临床实践,用于监测PTC患者的远处转移。
研究设计与样本
- 回顾性分析2012至2018年收集的患者临床样本,采用T细胞受体测序(TCR-seq)进行临床探索,研究在浙江省肿瘤医院开展。
- 纳入68例不同转移状态的甲状腺乳头状癌(PTC)患者和21例良性结节患者,所有患者术前均未接受任何治疗。
- 通过高通量测序测定每例患者TCRβ互补决定区3(CDR3)的特征。
主要发现
- 恶性肿瘤TCRβ多样性在血液(Shannon指数,P<.01)和肿瘤样本(Shannon指数,P<.001)中均显著高于良性结节。
- 伴远处转移的恶性肿瘤TCRβ多样性低于无转移的恶性肿瘤(Shannon指数,P<.01),伴侵袭性的恶性肿瘤低于无侵袭性者(Shannon指数,P<.01)。
- Morisita-Horn相似性指数分析显示,远处转移患者肿瘤与血液之间TCRβ组库相似性显著(与非转移者比较,P<.05)。
- 根据不同临床病理状态患者间CDR3的差异构建分类器以区分远处转移个体,基于重叠CDR3克隆型数量获得的曲线下面积为83.8%。
关键数值与推荐
- 恶性肿瘤与良性结节TCRβ多样性比较:血液Shannon指数P<.01,肿瘤Shannon指数P<.001。
- 远处转移与无转移恶性肿瘤TCRβ多样性比较:Shannon指数P<.01;侵袭性与无侵袭性比较:Shannon指数P<.01。
- 远处转移患者肿瘤与血液TCRβ组库相似性(Morisita-Horn相似性指数)与非转移者比较P<.05。
- 基于重叠CDR3克隆型数量的分类器区分远处转移个体的曲线下面积为83.8%。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
CONTEXT: Malignant thyroid tumor with distant metastasis is associated with poor outcome. Early detection of distant metastasis is of great clinical importance. OBJECTIVE: Thyroid tumor infiltrated with T cells can serve as a biomarker for monitoring metastasis. DESIGN: A retrospective analysis was performed of patient clinical samples collected between 2012 to 2018, using T-cell receptor sequencing (TCR-seq) for clinical exploration. SETTING: This study took place at Zhejiang Cancer Hospital. PATIENTS: Sixty-eight patients with papillary thyroid cancer (PTC) (distinct metastatic status) and 21 patients with benign nodules were enrolled. All patients had not received any treatment before surgery. MAIN OUTCOME MEASURE: The characteristics of TCRβ complementary-determining region 3 (CDR3) for each patient were determined by high-throughput sequencing. RESULTS: The TCRβ diversity of malignant tumors is significantly higher than benign nodules both in blood and tumor samples (Shannon index, blood, P < .01; tumor, P < .001). The malignant tumors with distant metastasis or invasiveness showed lower TCRβ diversity than nonmetastasis (Shannon index, P < .01) or noninvasive (Shannon index, P < .01) malignant tumors. Analysis of the Morisita-Horn similarity index indicated significant TCRβ repertoire similarity between tumor and blood in distant-metastatic patients (comparison with nonmetastasis, P < .05). According to the discrepancy of the CDR3 among patients with different clinicopathological status, the classifier was constructed to discriminate distant-metastatic individuals. A promising area under the curve value of 83.8% was obtained with the number of overlapping CDR3 clonotypes. CONCLUSION: The availability and reliability of TCR-seq render it prospective to translate these intrinsic attributes into clinical practice for monitoring distant metastasis in PTC patients.
引用
- Lan X, Cao J, Ye K, et al. TCR-Seq Identifies Distinct Repertoires of Distant-Metastatic and Nondistant-Metastatic Thyroid Tumors. J Clin Endocrinol Metab. 2020. PMID: 32674137. doi:10.1210/clinem/dgaa452
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。